New data finds AstraZeneca booster generates higher antibodies vs Omicron

admin

imageDOH’s new guidelines cut COVID isolation, quarantine time for fully vaccinated

The company said it adds to the growing evidence that supports a third dose of its vaccine irrespective of the primary vaccination schedule.

“These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against COVID-19,” Oxford Vaccine Group chief Andrew Pollard said in a statement.

A major British trial in December found that AstraZeneca’s shot increased antibodies when given as a booster after initial vaccination with its own shot or Pfizer’s, which is based on mRNA technology.

However, the study concluded that mRNA vaccines made by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.Subscribe to our daily newsletter By providing an email address.I agree to the Terms of Use and acknowledge that I have read the Privacy Policy .For more news about the novel coronavirus click here.

What you need to know about Coronavirus.For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next.

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

From living rooms to landfills, some holiday shopping returns take a 'very sad path'

Enlarge this image A postal worker carries packages through the snow on Jan.3 in Washington, D.C.Sarah Silbiger/Getty Images Sarah Silbiger/Getty Images A postal worker carries packages through the snow on Jan.3 in Washington, D.C. Sarah Silbiger/Getty Images More than half a trillion dollars.That’s the estimated value of all the stuff […]
From living rooms to landfills, some holiday shopping returns take a ‘very sad path’

Subscribe US Now